867:HKEXChina Medical System Holdings Ltd. Analysis

Kamdar Group (M) Berhad trades at MYR 0.195, well below its DCF‑derived fair value of roughly MYR 0.70, implying a substantial undervaluation. The price‑to‑book ratio of 0.18 and price‑to‑sales of 0.54 further underscore the cheapness. However, the company posted a trailing EPS of –0.05 and a negative profit margin of –7.5%, with operating and gross margins under 40%, indicating weak profitability. The balance sheet is heavily leveraged – total debt of MYR 82.9 million dwarfs cash of only MYR 6.2 million, yielding a debt‑to‑equity of nearly 39. The RSI sits at 25, suggesting the stock is oversold, while the MACD histogram remains negative, pointing to bearish momentum. Volume has been decreasing, and the beta of 0.16 signals limited market‑wide price sensitivity, yet 30‑day volatility is above 16%, reflecting price swings. The maximum historical drawdown of about 29% adds to the downside risk.
Despite the earnings drag, operating cash flow of MYR 17.2 million and free cash flow of MYR 16.6 million provide a modest liquidity cushion, and the extreme‑greed sentiment index (89.6) hints at market optimism that may not be fully justified. The lack of dividend and a “none” analyst recommendation further limit upside catalysts. In summary, the stock is deeply discounted relative to intrinsic estimates but faces significant earnings, debt and liquidity challenges, making a cautious stance appropriate.